Salivary gland cancer in the setting of tumor microenvironment: Translational routes for therapy

• Published in: Critical reviews in oncology/hematology Vol. 171; p. 103605
• Main Authors: Lavareze, Luccas, Scarini, João Figueira, de Lima-Souza, Reydson Alcides, Emerick, Carolina, Sales de Sá, Raísa, Aquino, Iara Gonçalves, Fernandes, Patricia Maria, Gonçalves, Mayara Trevizol, Helms, My N., Altemani, Albina, Egal, Erika Said Abu, Mariano, Fernanda Viviane
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-03-2022
• Subjects: Carcinoma; Humans; Immunotherapy; In vitro models; In vivo models; Review; Salivary gland carcinoma; Salivary Gland Neoplasms - pathology; Salivary Gland Neoplasms - therapy; Salivary Glands - pathology; Tumor Microenvironment; CXCL; MMTV; SACC; DAVID; In vivo models; TGFβR; SDC; PI3K; GLUT-1; MC; PD-L; EMMPRIN; KEGG; EMC; WHO; IL; NSG; FGF; CAF; EMP; MEC; MAPK; EMT; HLA-G; MMP; CTL-4; HNSCC; CXPA; NK; PD-1; iPANDA; In vitro models; PLAG1; IGFR; Review; AdNOS; EGFR; Mtor; OC; Salivary gland carcinoma; UBF; GEMM; ISH; ACC; OSCC; NPM1; Tumor microenvironment; PDX; VEGF; AKT; CCL; TME; SGC; PA; STAT; CCR; JAK; FASN; RAF; VEGFR-2; TGFβ; IPA; TILs; CXR
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2022.103605

•In vitro models is the starting point for the development of targeted therapy in salivary gland cancer.•Animal models represent an excellent tool to investigate the microenvironment in these tumors.•PDX-humanized models are the most suitable for the study of drugs and patient treatment.
Salivary gland carcinomas (SGC) are aggressive cancers that arise in minor and major salivary glands. Given the complexity and the multiple subtypes of this class of tumors, diagnosis and, treatment may be challenging for clinicians. Recently the tumor microenvironment, composed mainly of immune and stromal cells are been a target for treatment. Accumulating evidence indicates that cancer immunotherapies have made a significant impact on oncologic patients, however immunotherapeutic attempts in SGC have been shown limited improvement. Advances in the models that best translate aggressive SGC are needed for the development of clinical protocols grouping immunotherapies and other classes of drugs that will promote better responses in patients with advanced SGC stages. In this review, we introduced different experimental models for SGC with a focus on tumor microenvironment highlighting potential therapy applications for each model.